CS263952B1 - Remedy with antiviral effect - Google Patents
Remedy with antiviral effect Download PDFInfo
- Publication number
- CS263952B1 CS263952B1 CS853018A CS301885A CS263952B1 CS 263952 B1 CS263952 B1 CS 263952B1 CS 853018 A CS853018 A CS 853018A CS 301885 A CS301885 A CS 301885A CS 263952 B1 CS263952 B1 CS 263952B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- formula
- compounds
- virus
- cells
- effect
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 11
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- -1 alkali metal salts Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 241000450599 DNA viruses Species 0.000 abstract description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 19
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- 241000700618 Vaccinia virus Species 0.000 description 8
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001790 virustatic effect Effects 0.000 description 2
- GSLQFBVNOFBPRJ-YFKPBYRVSA-N (2s)-3-(6-aminopurin-9-yl)propane-1,2-diol Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)CO GSLQFBVNOFBPRJ-YFKPBYRVSA-N 0.000 description 1
- MZCFKCFREQWYEZ-XJSQPNRTSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(=O)[nH]c1=O.OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(=O)[nH]c1=O MZCFKCFREQWYEZ-XJSQPNRTSA-N 0.000 description 1
- VAQOTZQDXZDBJK-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethanol Chemical compound NC1=NC=NC2=C1N=CN2CCO VAQOTZQDXZDBJK-UHFFFAOYSA-N 0.000 description 1
- UHOFECKRSHSYNE-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)-2-hydroxypropanoic acid Chemical class NC1=NC=NC2=C1N=CN2CC(O)C(O)=O UHOFECKRSHSYNE-UHFFFAOYSA-N 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003559 chemosterilizing effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- LIEMBEWXEZJEEZ-UJURSFKZSA-N d-eritadenine Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-UJURSFKZSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS853018A CS263952B1 (en) | 1985-04-25 | 1985-04-25 | Remedy with antiviral effect |
| IL78553A IL78553A (en) | 1985-04-25 | 1986-04-21 | Therapeutic compositions of phosphonylmethoxyalkyl adenines |
| US06/854,087 US4724233A (en) | 1985-04-25 | 1986-04-21 | Therapeutical application of phosphonylmethoxyalkyl adenines |
| AU56468/86A AU586860B2 (en) | 1985-04-25 | 1986-04-22 | Therapeutical application of phosphonylmethoxyalkyl adenines |
| DK184186A DK167342B1 (da) | 1985-04-25 | 1986-04-22 | Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet |
| EG241/86A EG18436A (en) | 1985-04-25 | 1986-04-24 | Therapeutical application of phosponylmethoxy-alkyl adenines |
| NZ215939A NZ215939A (en) | 1985-04-25 | 1986-04-24 | Phosphonyl methoxyadenine antiviral compositions |
| GR861089A GR861089B (en) | 1985-04-25 | 1986-04-24 | Therapeutic application of phosponylmethoxy alkyl ademines |
| CA000507510A CA1272956A (en) | 1985-04-25 | 1986-04-24 | Therapeutical application of phosphonylmethoxy-alkyl adenines |
| PH33699A PH23112A (en) | 1985-04-25 | 1986-04-24 | Therapeutical application of phosphonylmethoxyalkyl adenines |
| PT82457A PT82457B (pt) | 1985-04-25 | 1986-04-24 | Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral |
| ZA863133A ZA863133B (en) | 1985-04-25 | 1986-04-25 | Therapeutical application of phosphonylmethoxyalkyl adenines |
| AT86105776T ATE73663T1 (de) | 1985-04-25 | 1986-04-25 | Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten. |
| EP86105776A EP0205826B1 (de) | 1985-04-25 | 1986-04-25 | Phosphonylmethoxyalkyl-Adeninen zur Behandlung von Viruskrankheiten |
| JP61097811A JPH0692307B2 (ja) | 1985-04-25 | 1986-04-25 | アデニン誘導体の治療的適用 |
| DE8686105776T DE3684363D1 (de) | 1985-04-25 | 1986-04-25 | Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten. |
| HK217296A HK217296A (en) | 1985-04-25 | 1996-12-19 | Phosphonylmethoxyalkyl adenines for the treatment of virus diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS853018A CS263952B1 (en) | 1985-04-25 | 1985-04-25 | Remedy with antiviral effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS263952B1 true CS263952B1 (en) | 1989-05-12 |
Family
ID=5369042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS853018A CS263952B1 (en) | 1985-04-25 | 1985-04-25 | Remedy with antiviral effect |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4724233A (de) |
| EP (1) | EP0205826B1 (de) |
| JP (1) | JPH0692307B2 (de) |
| AT (1) | ATE73663T1 (de) |
| AU (1) | AU586860B2 (de) |
| CA (1) | CA1272956A (de) |
| CS (1) | CS263952B1 (de) |
| DE (1) | DE3684363D1 (de) |
| DK (1) | DK167342B1 (de) |
| EG (1) | EG18436A (de) |
| GR (1) | GR861089B (de) |
| HK (1) | HK217296A (de) |
| IL (1) | IL78553A (de) |
| NZ (1) | NZ215939A (de) |
| PH (1) | PH23112A (de) |
| PT (1) | PT82457B (de) |
| ZA (1) | ZA863133B (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047533A (en) * | 1983-05-24 | 1991-09-10 | Sri International | Acyclic purine phosphonate nucleotide analogs |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| IL84477A (en) * | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| US5284837A (en) * | 1988-05-06 | 1994-02-08 | Medivir Ab | Derivatives of purine, process for their preparation and a pharmaceutical preparation |
| EP0353955A3 (de) * | 1988-08-02 | 1991-08-14 | Beecham Group Plc | Chemische Verbindungen |
| US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| EP0481214B1 (de) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| HU225970B1 (en) * | 1991-10-11 | 2008-01-28 | Acad Of Science Czech Republic | Antiviral acyclic phosphonomethoxyalkyl-substituted alkenyl purine and pyrimidine derivatives, and pharmaceutical preparations containing them |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| AU690587B2 (en) * | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| EP0754046A1 (de) * | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Verwendung der phosphonylmethoxyalkyl-nukleoside zur behandlung des erhöhten innenaugendrucks |
| US5468752A (en) * | 1994-04-04 | 1995-11-21 | Freeman; William R. | Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| TWI230618B (en) * | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
| US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| US20030187261A1 (en) * | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| AU8294101A (en) | 2000-07-21 | 2002-02-05 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| CZ297267B6 (cs) * | 2001-06-29 | 2006-10-11 | Ústav organické chemie a biochemie AV CR | Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující |
| NZ536327A (en) * | 2002-05-13 | 2007-08-31 | Metabasis Therapeutics Inc | PMEA and PMPA cyclic producing synthesis |
| AU2003299492B2 (en) * | 2002-05-13 | 2010-06-10 | Metabasis Therapeutics, Inc. | Cyclic prodrugs of PMEA one of its analogues |
| RU2225223C1 (ru) * | 2002-06-14 | 2004-03-10 | Закрытое акционерное общество Фирма "ВИТАФАРМА" | Лиофилизированная антигерпетическая вакцина |
| WO2004043972A1 (fr) * | 2002-11-12 | 2004-05-27 | Tianjin Kinsly Pharmaceutical Co., Ltd. | Nouvelle forme cristalline d'adefovir dipivoxil et sa composition |
| EA201100293A1 (ru) * | 2003-01-14 | 2011-08-30 | Джилид Сайэнс, Инк. | Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции |
| WO2004111064A1 (en) | 2003-06-16 | 2004-12-23 | Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| CA2565966A1 (en) * | 2004-06-08 | 2005-12-29 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| CN100338080C (zh) * | 2004-06-16 | 2007-09-19 | 山东中科泰斗化学有限公司 | 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法 |
| HRP20070078A2 (hr) | 2004-07-27 | 2007-05-31 | Gilead Sciences | Fosfonatni analozi spojeva koji inhibiraju hiv |
| US8101745B2 (en) | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| FR2908133B1 (fr) | 2006-11-08 | 2012-12-14 | Centre Nat Rech Scient | Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux |
| RU2443703C2 (ru) | 2007-06-18 | 2012-02-27 | Саншайн Лейк Фарма Ко., Лтд | Бром-фенил замещенные тиазолилдигидропиримидины |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| SG172060A1 (en) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| CN102365283B (zh) | 2009-03-26 | 2014-04-09 | 株式会社大熊制药 | 阿德福韦酯的新晶型及其制备方法 |
| US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| CN104666315A (zh) | 2010-12-10 | 2015-06-03 | 西格玛制药实验有限责任公司 | 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物 |
| SG10201800188SA (en) | 2013-03-15 | 2018-02-27 | Univ California | Acyclic nucleoside phosphonate diesters |
| WO2015038421A1 (en) | 2013-09-10 | 2015-03-19 | Dow Corning Corporation | Wear-resistant silicon eutectic alloy components and methods of making the same |
| WO2015123352A1 (en) | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| WO2015195538A1 (en) | 2014-06-17 | 2015-12-23 | Dow Corning Corporation | Decorative shape-cast articles made from silicon eutectic alloys, and methods for producing the same |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| CN113577081A (zh) | 2014-07-11 | 2021-11-02 | 吉利德科学公司 | 用于治疗hiv的toll样受体调节剂 |
| HRP20220651T1 (hr) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nukleotidni analozi |
| WO2017048956A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Nucleotide analogs |
| JP2018527366A (ja) | 2015-09-15 | 2018-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター |
| EP3372227A1 (de) | 2017-03-06 | 2018-09-12 | MH10 Spolka z ograniczona odpowiedzialnoscia | Tablettenformulierung von adefovir dipivoxil |
| CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
| WO2024020127A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| JPS52105195A (en) * | 1976-03-01 | 1977-09-03 | Wellcome Found | Substituted purine |
| US4230708A (en) * | 1977-10-20 | 1980-10-28 | Stichting Rega V.Z.W. | Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| CS238038B1 (en) * | 1983-10-07 | 1985-11-13 | Antonin Holy | Medical drug with antivirus effect |
-
1985
- 1985-04-25 CS CS853018A patent/CS263952B1/cs not_active IP Right Cessation
-
1986
- 1986-04-21 IL IL78553A patent/IL78553A/xx not_active IP Right Cessation
- 1986-04-21 US US06/854,087 patent/US4724233A/en not_active Expired - Lifetime
- 1986-04-22 AU AU56468/86A patent/AU586860B2/en not_active Ceased
- 1986-04-22 DK DK184186A patent/DK167342B1/da not_active IP Right Cessation
- 1986-04-24 PT PT82457A patent/PT82457B/pt unknown
- 1986-04-24 EG EG241/86A patent/EG18436A/xx active
- 1986-04-24 PH PH33699A patent/PH23112A/en unknown
- 1986-04-24 GR GR861089A patent/GR861089B/el unknown
- 1986-04-24 NZ NZ215939A patent/NZ215939A/xx unknown
- 1986-04-24 CA CA000507510A patent/CA1272956A/en not_active Expired - Lifetime
- 1986-04-25 AT AT86105776T patent/ATE73663T1/de not_active IP Right Cessation
- 1986-04-25 DE DE8686105776T patent/DE3684363D1/de not_active Expired - Lifetime
- 1986-04-25 EP EP86105776A patent/EP0205826B1/de not_active Expired - Lifetime
- 1986-04-25 JP JP61097811A patent/JPH0692307B2/ja not_active Expired - Lifetime
- 1986-04-25 ZA ZA863133A patent/ZA863133B/xx unknown
-
1996
- 1996-12-19 HK HK217296A patent/HK217296A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK167342B1 (da) | 1993-10-18 |
| CA1272956A (en) | 1990-08-21 |
| PT82457A (en) | 1986-05-01 |
| EG18436A (en) | 1993-02-28 |
| JPH0692307B2 (ja) | 1994-11-16 |
| DE3684363D1 (de) | 1992-04-23 |
| PT82457B (pt) | 1988-03-03 |
| DK184186A (da) | 1986-10-26 |
| ZA863133B (en) | 1987-02-25 |
| EP0205826A2 (de) | 1986-12-30 |
| HK217296A (en) | 1996-12-27 |
| JPS61275218A (ja) | 1986-12-05 |
| AU586860B2 (en) | 1989-07-27 |
| AU5646886A (en) | 1986-10-30 |
| DK184186D0 (da) | 1986-04-22 |
| NZ215939A (en) | 1988-09-29 |
| IL78553A (en) | 1989-09-28 |
| US4724233A (en) | 1988-02-09 |
| IL78553A0 (en) | 1986-08-31 |
| ATE73663T1 (de) | 1992-04-15 |
| EP0205826B1 (de) | 1992-03-18 |
| GR861089B (en) | 1986-08-26 |
| EP0205826A3 (en) | 1989-05-10 |
| PH23112A (en) | 1989-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS263952B1 (en) | Remedy with antiviral effect | |
| De Clercq | Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections | |
| De Clercq | S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents | |
| Clercq et al. | A novel selective broad-spectrum anti-DNA virus agent | |
| US5321030A (en) | Creatine analogs having antiviral activity | |
| De Clercq et al. | In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds | |
| De Clercq et al. | Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus | |
| CA2222154A1 (en) | Acyclovir derivatives for topical use | |
| Zakirova et al. | Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro | |
| JP4545434B2 (ja) | 抗ウイルス活性を有する６−‘２−（ホスホノメトキシ）アルコキシピリミジン誘導体 | |
| De Clercq | The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine | |
| AU623341B2 (en) | Antiviral therapy for hepatitis b | |
| EP0294443B1 (de) | Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden | |
| JPH0618786B2 (ja) | 医薬組成物 | |
| Machida et al. | In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil | |
| De Clercq et al. | Effects of E-5-(2-bromovinyl)-2'-deoxyuridine and other selective anti-herpes compounds on the induction of retrovirus particles in mouse BALB/3T3 cells | |
| CA1328865C (en) | Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabino- furanosyl)-5-ethyluracil | |
| Krečmerová | Nucleoside and nucleotide analogues for the treatment of herpesvirus infections: Current stage and new prospects in the field of acyclic nucleoside phosphonates | |
| Ayisi et al. | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses | |
| Brandi et al. | A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity | |
| Park et al. | Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice | |
| Barnard et al. | Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses | |
| Holliday et al. | Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine | |
| Michaelis et al. | In vitro antiviral activity of aphidicolin and its derivates | |
| Johnson et al. | Synergistic inhibition of anatid herpesvirus replication by acyclovir and phosphonocompounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Effective date: 20000425 |